RGNX · REGENXBIO Inc. · Executive Compensation
$7.64
-0.39 (-4.86%)
At close · Nov 13
Return incl. dividend (before tax)
Play latest call
Q3 2026 earnings call transcript
Going-concern doubt
— flagged Nov 5, 2026
Substantial doubt about the company's ability to continue as a going concern.
“These conditions raise substantial doubt about our ability to continue as a going concern within 12 months from the issuance date of our consolidated financial statements for the three and nine months ended September 30, 2026 included in this Quarterly Report on Form 10-Q.”View the 10-Q filed Nov 5, 2026
Market Cap
$505.18M
Shares
66.12M
Volume · Nov 13
716.16K
Avg daily vol (3M)
1.39M
You came from your AI assistant. Add Equibles to it and ask about this data directly, free.
Named-executive compensation from the company's DEF 14A proxy statements — salary, bonus, stock and option awards, non-equity incentive, and the company-reported total per executive per fiscal year, exactly as disclosed in the Summary Compensation Table.
Fiscal 2025
| Executive | Role | Total |
|---|---|---|
| Curran Simpson | President and Chief Executive Officer | $4,200,712 |
| Patrick Christmas | EVP, Chief Strategy and Legal Officer | $2,041,511 |
| Stephen Pakola | EVP, Chief Medical Officer | $1,799,546 |
Fiscal 2024
| Executive | Role | Total |
|---|---|---|
| Kenneth T. Mills | Former President and CEO | $5,507,038 |
| Curran Simpson | President and CEO | $4,784,543 |
| Mitchell Chan | EVP, Chief Financial Officer | $3,205,294 |
| Olivier Danos | EVP, Chief Scientific Officer | $2,956,949 |
| Patrick Christmas | EVP, Chief Strategy and Legal Officer | $2,737,813 |
| Stephen Pakola | EVP, Chief Medical Officer | $2,696,858 |
| Vit Vasista | Former EVP, Chief Financial Officer | $2,226,951 |
Fiscal 2023
| Executive | Role | Total |
|---|---|---|
| Kenneth T. Mills | Former President and CEO | $5,916,713 |
| Stephen Pakola | EVP, Chief Medical Officer | $3,305,985 |
| Olivier Danos | EVP, Chief Scientific Officer | $2,985,416 |
| Curran Simpson | President and CEO | $2,950,002 |
| Vit Vasista | Former EVP, Chief Financial Officer | $2,618,404 |
Fiscal 2022
| Executive | Role | Total |
|---|---|---|
| Kenneth T. Mills | Former President and CEO | $5,753,713 |
| Olivier Danos | EVP, Chief Scientific Officer | $2,147,828 |
| Curran Simpson | President and CEO | $2,097,463 |
| Stephen Pakola | EVP, Chief Medical Officer | $1,854,615 |
| Vit Vasista | Former EVP, Chief Financial Officer | $1,852,260 |
Fiscal 2021
| Executive | Role | Total |
|---|---|---|
| Kenneth T. Mills | President and CEO | $8,622,941 |
| Patrick Christmas | EVP, Chief Legal Officer | $3,438,888 |
| Vit Vasista | EVP, Chief Financial Officer | $3,346,165 |
| Curran Simpson | EVP, Chief Operating Officer | $3,247,167 |
| Olivier Danos | EVP, Chief Scientific Officer | $2,797,694 |
Fiscal 2020
| Executive | Role | Total |
|---|---|---|
| Kenneth T. Mills | President and CEO | $7,644,087 |
| Vit Vasista | EVP, Chief Financial Officer | $1,881,639 |
| Patrick Christmas | EVP, Chief Legal Officer | $1,843,929 |
| Olivier Danos | EVP, Chief Scientific Officer | $1,805,415 |
| Curran Simpson | EVP, Chief Operating Officer | $1,750,865 |
Fiscal 2019
| Executive | Role | Total |
|---|---|---|
| Kenneth T. Mills | President and CEO | $6,147,269 |
| Steve Pakola | Senior Vice President, Chief Medical Officer | $3,908,793 |
| Vit Vasista | EVP, Chief Financial Officer | $2,184,616 |
| Olivier Danos | EVP, Chief Scientific Officer | $1,926,420 |
| Patrick Christmas | EVP, Chief Legal Officer | $1,833,033 |
| Curran Simpson | EVP, Chief Operations and Technology Officer | $1,825,744 |
Fiscal 2018
| Executive | Role | Total |
|---|---|---|
| Kenneth T. Mills | President and CEO | $4,938,199 |
| Vit Vasista | Senior Vice President, Chief Financial Officer | $1,944,391 |
| Curran Simpson | Senior Vice President, Chief Operations and Technology Officer | $1,901,142 |
| Olivier Danos | Senior Vice President, Chief Scientific Officer | $1,613,769 |
Executive changes
| Person | Role | Change | Filed |
|---|---|---|---|
| George Migausky | Chairman of the Board | Appointed | 2026-10-16 |
| Kenneth T. Mills | board of directors | Resigned | 2026-10-16 |
| A.N. "Jerry" Karabelas, Ph.D. | director | Resigned | 2026-08-25 |
| Jean Bennett, M.D., Ph.D. | director | Resigned | 2026-08-25 |
| Gregory Ciongoli | Class II director | Appointed | 2026-08-25 |
| Vittal Vasista | Executive Vice President, Chief Financial Officer and Principal Accounting Officer | Resigned | 2024-09-17 |
| Vittal Vasista | Principal Accounting Officer | Resigned | 2024-09-17 |
| Mitchell Chan | Principal Accounting Officer | Appointed | 2024-09-17 |
| Mitchell Chan | Executive Vice President, Chief Financial Officer and Principal Accounting Officer | Appointed | 2024-09-17 |
| Daniel Tassé | Lead Independent Director | Appointed | 2024-06-13 |
| Curran M. Simpson | Class I director | Appointed | 2024-06-13 |
| Curran M. Simpson | President and Chief Executive Officer | Appointed | 2024-06-13 |
| Kenneth T. Mills | Chairman of the Board | Appointed | 2024-06-13 |
| Kenneth T. Mills | President and Chief Executive Officer | Resigned | 2024-06-13 |
| Curran M. Simpson | Chief Operating Officer | Appointed | 2023-01-10 |
Leadership
- Curran M. Simpson CEO, COO, Board Member
- Allan M. Fox Chairman, Board Member
- George Migausky Chairman, Board Member
- Kenneth T. Mills Chairman
- Mitchell Chan Chief Accounting Officer
- Alexandra Glucksmann Board Member
- Alexandra Glucksmann, Ph.D. Board Member
- Curran Simpson Board Member
- Daniel Tassé Board Member
- David Stump Board Member
- George V. Migausky Board Member
- Gregory Ciongoli Board Member
- Jean Bennett Board Member
- Jennifer Zachary Board Member
- Kenneth Mills Board Member
Key facts
CIK
1590877
CUSIP
75901B107
13F (30d)
127 filings
113 filers
Visit website
Investor relations